Literature DB >> 7004344

Comparative susceptibilities of clinical isolates of Serratia marcescens to newer cephalosporins, alone and in combination with various aminoglycosides.

S M Markowitz, D J Sibilla.   

Abstract

We examined 100 clinically significant isolates of Serratia marcescens for susceptibility to newer cephalosporin and cephamycin antibiotics, alone and in combination with various aminoglycosides. Moxalactam and cefotaxime were the most effective agents; all isolates were inhibited by 25 and 50 micrograms/ml, respectively. All strains were susceptible to amikacin at concentrations safely achievable in serum, whereas gentamicin, netilmicin, and tobramycin inhibited 63, 63, and 16% of the isolates, respectively. Moxalactam, cefotaxime, and amikacin were active against gentamicin-susceptible and gentamicin-resistant strains. Studies of synergy revealed that moxalactam and cefotaxime, in combination with netilmicin or amikacin, were often synergistic and infrequently antagonistic against cephalothin- and gentamicin-resistant strains. These results suggest that moxalactam and cefotaxime, alone or in combination, may be efficacious in treating infections due to multiply antibiotic-resistant S. marcescens.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7004344      PMCID: PMC284070          DOI: 10.1128/AAC.18.5.651

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  31 in total

1.  Polymyxin B and rifampin: new regimen for multiresistant Serratia marcescens infections.

Authors:  R C Ostenson; B T Fields; C M Nolan
Journal:  Antimicrob Agents Chemother       Date:  1977-12       Impact factor: 5.191

2.  In vitro studies on netilmicin, a new aminoglycoside antibiotic.

Authors:  D Stewart; G P Bodey; B LeBlanc
Journal:  Antimicrob Agents Chemother       Date:  1977-06       Impact factor: 5.191

3.  Serial dilution antibiotic sensitivity testing with the microtitrator system.

Authors:  J H Marymont; R M Wentz
Journal:  Am J Clin Pathol       Date:  1966-05       Impact factor: 2.493

4.  Antibiotic resistance patterns of clinical isolates of Serratia marcescens.

Authors:  R C Cooksey; E R Bannister; W E Farrar
Journal:  Antimicrob Agents Chemother       Date:  1975-04       Impact factor: 5.191

5.  An outbreak of nosocomial infection due to multiply resistant Serratia marcescens: evidence of interhospital spread.

Authors:  D R Schaberg; R H Alford; R Anderson; J J Farmer; M A Melly; W Schaffner
Journal:  J Infect Dis       Date:  1976-08       Impact factor: 5.226

6.  Sulfamethoxazole-trimethoprim-polymyxin therapy of serious multiply drug-resistant Serratia infections.

Authors:  F E Thomas; J M Leonard; R H Alford
Journal:  Antimicrob Agents Chemother       Date:  1976-02       Impact factor: 5.191

7.  Amikacin therapy. Use against infections caused by gentamicin- and tobramycin-resistant organisms.

Authors:  V L Yu; F S Rhame; E L Pesanti; S G Axline
Journal:  JAMA       Date:  1977-08-29       Impact factor: 56.272

8.  Comparison of methods for assessing in vitro antibiotic synergism against Pseudomonas and Serratia.

Authors:  R J Weinstein; L S Young; W L Hewitt
Journal:  J Lab Clin Med       Date:  1975-11

9.  Antimicrobial activity in vitro of netilmicin and comparison with sisomicin, gentamicin, and tobramycin.

Authors:  B R Meyers; S Z Hirschman
Journal:  Antimicrob Agents Chemother       Date:  1977-01       Impact factor: 5.191

10.  Activity of netilmicin compared with those of gentamicin and tobramycin against enterobacteria and Pseudomonas aeruginosa.

Authors:  P Chadwick; S Salmon; B Taylor
Journal:  Antimicrob Agents Chemother       Date:  1977-09       Impact factor: 5.191

View more
  8 in total

1.  Comparative in vitro activities of azlocillin-cefotaxime and azlocillin-tobramycin combinations against blood and multi-drug resistant bacterial isolates.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

2.  Early synergistic interactions between amikacin and six beta-lactam antibiotics against multiply resistant members of the family Enterobacteriaceae.

Authors:  R H Glew; R A Pavuk
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

3.  Synergism between aminoglycosides and cephalosporins with antipseudomonal activity: interaction index and killing curve method.

Authors:  H O Hallander; K Dornbusch; L Gezelius; K Jacobson; I Karlsson
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

4.  Outer membrane and porin characteristics of Serratia marcescens grown in vitro and in rat intraperitoneal diffusion chambers.

Authors:  F Malouin; G D Campbell; M Halpenny; G W Becker; T R Parr
Journal:  Infect Immun       Date:  1990-05       Impact factor: 3.441

5.  Outbreak of nosocomial urinary tract infections caused by Serratia marcescens.

Authors:  T Okuda; N Endo; Y Osada; H Zen-Yoji
Journal:  J Clin Microbiol       Date:  1984-10       Impact factor: 5.948

6.  Comparative in vitro activities of beta-lactam-tobramycin combinations against Pseudomonas aeruginosa and multidrug-resistant gram-negative enteric bacilli.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1982-06       Impact factor: 5.191

Review 7.  Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; J A Romankiewicz; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-10       Impact factor: 9.546

Review 8.  Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-03       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.